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A 17 year old man presented in November 2010 to Queen 
Elizabeth Central Hospital (QECH) with acute shortness of  
breath and bilateral leg weakness.
His symptoms had started gradually in July 2010 with weak-
ness of  his right leg .  After two weeks  his left leg also be-
came weak.  He found it particularly difficult to get up from 
a chair. Despite his weakness, he was still able to walk inde-
pendently.  At this point he sought medical advice at QECH; 
a definitive diagnosis was not made.
By August 2010 his weakness also involved both his arms, 
so that he was unable to raise them above his head.  He 
noticed that he fatigued easily, especially at the end of  the 
day, and he became breathless when doing simple tasks like 
walking to the toilet. He again went to QECH; on this occa-
sion he had a series of  investigations which included a nor-
mal Chest X-ray and X-ray of  his spine. Blood examination 
showed that he was HIV negative and his full blood count 
was unremarkable.
By September, his voice was slurred and he frequently lost 
control of  his speech; he described this as “speaking in 
tongues”.   Sometimes by the end of  the day he could see 
two images when looking to the side, and occasionally he 
had difficulty swallowing liquids. A presumptive diagnosis of  
peripheral neuropathy was made and he was given a week tri-
al of  20mg of  prednisolone. He showed very little improve-
ment during treatment with steroids. 
Approximately 2 weeks after his trial of  steroid therapy, he 
noted a rapid deterioration in his symptoms; he was partic-
ularly concerned about his breathlessness and bilateral leg 
weakness. He denied symptoms of  numbness / paraesthe-
siae, he had no sphincter disturbance and he suffered no fe-
ver, night sweats or unintentional weight loss. 
He was well prior to the onset of  his symptoms in July 2010; 
he had been performing well at school and had normal de-
velopmental milestones. He did not use any illicit drugs and 
there was no family history of  any neurological conditions.
On examination
The patient was lethargic and was unable to hold his head 
up. He was afebrile, normotensive and had a pulse rate of  
75 beats per minute. He had a respiratory rate of  16 breaths 
per minute and his oxygen saturation while breathing air 
was 96%.  Cardiovascular, respiratory and abdominal ex-
aminations were unremarkable.  Cranial nerve examination 
revealed double vision during  lateral gaze in either direc-
tion.   There was, however, no overt evidence of  opthalmo-
plegia.  The remainder of  his cranial nerves were normal. 
He had symmetrical proximal muscle weakness of  his up-
per and lower limbs; this included neck flexion (MRC score 
3/5), abduction and adduction of  his shoulders (MRC 3/5), 
flexion of  his elbows (MRC 4/5), flexion and extension of  
his hips (MRC 3/5) and flexion and extension of  his knees 
(MRC 4/5). His reflexes were intact, plantars were downgo-
ing and all his sensory modalities were normal. There was 
no evidence of  mal-coordination, muscle wasting or muscle 
fasciculation. 
One striking observation was that he was easily fatigable af-
ter repeated movement of  his shoulder (Figure 1).
Investigations
Full blood count: Hb 13.4g/dl, wbc 6.0x109/L, platelets 
300x109/L. A repeat HIV test was negative and Chest X-ray 
normal. CSF analysis: WCC 0, RCC 0, glucose 3.28mmol/l, 
protein 0.33g/l.
We administered a drug that resulted in a full (transient) re-
covery of  his muscle weakness; this response revealed the 
diagnosis (Figs 1 and 2)
Figure 1. (a) and (b) The patient makes repeated movements of the left 
arm; (c) He is now asked to raise the left arm, and is unable to do so.
Figure 2. After the administration of a drug, the patient develops full 
transient recovery.  He is now able to lift his left arm above his head 
and can resist the examiner pushing the left arm down. 
What was the drug?    What is the name of the test?    
What is the diagnosis?
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1) Edrophonium (Tensilon).  This is a short acting acetyl 
cholinesterase inhibitor
2) ‘Tensilon test’; the test is usually performed in a double 
blinded setting (i.e. placebo - usually 0.9% saline - versus 
edrophonium, with the clinician unaware of  which substance 
is being injected), monitoring for a transient improvement in 
muscle strength following the administration of  edrophonium 
but no improvement after saline.   If  this occurs, the test 
is positive. This test is usually done in an intensive care 
setting because edrophonium can cause bradycardia; cardiac 
monitoring, a prepared dose of  atropine and resuscitation 
equipment is usually advocated.
3) Myasthenia Gravis (MG)
MG is an autoimmune disease affecting the neuromuscular 
junction.  It is caused by auto antibodies against 
neuromuscular junction receptors (acetylcholine nicotinic 
receptors) which are essential for the contraction of  muscle.
The incidence of  this condition worldwide is approximately 
100 per million in a population. The incidence of  MG 
in sub-Saharan Africa is unknown.  The condition is 
probably under-recognised because of  its heterogeneous 
clinical presentation and also because of  the sophisticated 
diagnostic tests necessary to make a diagnosis.   Our case 
report indicates  that MG does exist in a sub-Saharan setting 
and should always be considered in patients presenting with 
exclusively motor symptoms.
MG has a bimodal age of  onset. It can present early, as in 
our case, or late in life; the latter tends to be more common 
in men.  Patients typically present with extraocular muscle 
weakness and later limb and bulbar muscle weakness. This 
disease has a heterogeneous clinical syndrome and does 
not always follow a typical course, making the diagnosis 
sometimes difficult. In our case, the patient’s symptoms 
predominately affected his limbs; his extraocular muscles 
and bulbar symptoms were less obvious. 
Worsening of weakness after prolonged contraction 
or use (fatigability) is the hallmark of this condition.
There are many methods used to make a definitive diagnosis 
of  MG, some of  which can be used in a resource-limited 
setting like Malawi:
1) identifying serum antibody to acetylcholine receptor (these 
antibodies are found in 80-85% with generalised myasthenia 
gravis);
2) neurophysiology testing; repetitive nerve stimulation 
shows a decremental response, indicating a neuromuscular 
transmission blockade ;
3) edrophonium (Tensilon test) – which was the definitive 
test used in our case.  Edrophonium is a drug that is often 
used to reverse anaesthetic medications; where there is an 
anaesthetic department, this drug or its equivalent should 
also be available.
Our patient was started on symptomatic treatment 
with a cholinesterase inhibitor (pyridostigmine) and 
definitive treatment with high dose corticosteroid (an 
immunosuppressive agent). After 6 months of  treatment 
he went into remission with a low maintenance dose of  
steroid, and he did not require symptomatic treatment with 
pyridostigmine after 3 months. 
In some patients it can take many months on high-dose 
steroids to achieve maximal benefit. That is probably why 
there was minimal improvement following the initial trial of  
steroid in our patient.  A paradoxical worsening with steroids 
can be observed during its initiation – an effect thought to 
be due to a transient depletion of  acetylcholine stores.  This 
complication can be kept to a minimum by increasing the 
dose gradually and giving it on alternate days.  It may well 
be that the short cause of  steroid given for the presumptive 
diagnosis of  peripheral neuropathy may have exacerbated 
our patient’s symptoms.
A life–threatening complication of  MG is ‘myasthenic crisis’; 
this is a medical emergency that may progress to respiratory 
failure. There are important correctable conditions that 
should be treated and drugs that should be used with caution 
in patients with MG to avoid such a crisis (Table 1).
This case is an example of  a non-HIV related, treatable 
neurological condition that is probably often un-diagnosed. 
We have demonstrated that in a resource-limited setting 
we were able to make a definitive diagnosis of  MG and 
start appropriate treatment, which led to our patient’s  full 
recovery.
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Table 1. Exacerbating factors of MG and potential triggers of myasthenic 
crisis (modified from Jacob et al)
Infection Viral, bacterial, mycobacterial, 
fungal




Drugs Withdrawal of cholinesterase 
inhibitors (when symptoms not 
fully recovered)
Rapid introduction or increase of 
steroids
antimicrobials (e.g. gentamicin, 
ciprofloxacin, chloroquine)
Anti-hypertensives (e.g. 
beta-blockers and calcium chan
nel blockers)
Neuropsychiatric drugs (e.g. 
lithium, chlorpromazine, pheny
toin)
Botulinum toxin
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